<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Biosimilars Archive - ms-mcs</title>
	<atom:link href="https://www.ms-mcs.ch/category/biosimilars/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.ms-mcs.ch/category/biosimilars/</link>
	<description>Medical communication, medical affairs and commercialization services</description>
	<lastBuildDate>Thu, 19 Oct 2023 09:46:25 +0000</lastBuildDate>
	<language>de</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.4.8</generator>

<image>
	<url>https://www.ms-mcs.ch/wp-content/uploads/2020/12/cropped-mcs_icon-32x32.png</url>
	<title>Biosimilars Archive - ms-mcs</title>
	<link>https://www.ms-mcs.ch/category/biosimilars/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Medical Consensus</title>
		<link>https://www.ms-mcs.ch/consensus-process-biosimilars-multiple-sclerosis/</link>
		
		<dc:creator><![CDATA[wp_eawi0]]></dc:creator>
		<pubDate>Tue, 17 Oct 2023 16:20:10 +0000</pubDate>
				<category><![CDATA[Biosimilars]]></category>
		<category><![CDATA[multiple sclerosis]]></category>
		<guid isPermaLink="false">https://www.ms-mcs.ch/?p=1182</guid>

					<description><![CDATA[]]></description>
										<content:encoded><![CDATA[<div class="et_pb_section et_pb_section_0 et_section_regular" >
				
				
				
				
				
				
				<div class="et_pb_row et_pb_row_0">
				<div class="et_pb_column et_pb_column_4_4 et_pb_column_0  et_pb_css_mix_blend_mode_passthrough et-last-child">
				
				
				
				
				<div class="et_pb_with_border et_pb_module et_pb_text et_pb_text_0  et_pb_text_align_left et_pb_bg_layout_light">
				
				
				
				
				<div class="et_pb_text_inner"><h2><strong><img fetchpriority="high" decoding="async" class="wp-image-1278 size-medium alignleft" src="https://www.ms-mcs.ch/wp-content/uploads/2023/10/dna-double_helix-300x169.jpg" alt="double helix" width="300" height="169" />Consensus process.</strong></h2>
<p>Use of follow-on disease-modifying treatments for multiple sclerosis: Consensus recommendations <a href="https://journals.sagepub.com/doi/abs/10.1177/13524585221116269" target="_blank" rel="noopener">(Mult Scler. 2022 Dec;28(14):2177-2189.)</a>. Coordination of the consensus group, contribution to the systematic literature review and the revision of the manuscript. This project was funded by unrestricted educational grants from Viatris, Synthon and GL Pharma.</p></div>
			</div>
			</div>
				
				
				
				
			</div>
				
				
			</div>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
